What is the current stock price of ImmunityBio, Inc. (IBRX)?

As of the latest market data, ImmunityBio, Inc. (IBRX) is trading at $7.22. The stock has seen a loss of -6.72% today.

Does ImmunityBio, Inc. (IBRX) pay a dividend?

Based on current data, ImmunityBio, Inc. does not have a confirmed active dividend policy.

What is the market cap of ImmunityBio, Inc.?

The current market capitalization of ImmunityBio, Inc. (IBRX) is approximately unavailable.

IBRX

ImmunityBio, Inc.·Healthcare

7.22

6.718%(−0.52)

Market Closed

7.27

0.693%(+0.05)

After Hours

Last Updated: — ET

52W L: $1.9552W H: $12.43

IBRX NEWS

newsfilecorp.com

5h ago

IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

gurufocus.com

7h ago

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS PR N

prnewswire.com

7h ago

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

IBRX Investors with Losses Encouraged to Contact the Firm BeforeMay 26th Deadline SAN FRANCISCO, May 23, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio's lead biologic product (Anktiva), which the FDA said were misleading efficacy claims.

globenewswire.com

23h ago

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

globenewswire.com

23h ago

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

businesswire.com

1d ago

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”).

Company Profile

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Employees

671

IPO Date

2015-07-28

Beta

0.07

Websiteimmunitybio.com↗